News24.com | South Korea probing two deaths after AstraZeneca’s Covid-19 vaccine

  • South Korea authorities are investigating death after people received a Covid-19 vaccine.
  • Both people has pre-existing health conditions.
  • The country authorised the AstraZeneca and Pfizer vaccines.

South Korean authorities said on Wednesday they are investigating the deaths of two people after a media report said the pair – both with pre-existing conditions – died within days of receiving AstraZeneca’s Covid-19 vaccine.

LIVE | All the latest coronavirus and lockdown updates

A 63-year-old nursing home patient with cerebrovascular disease developed symptoms, including high fever, after being given the AstraZeneca vaccine, Yonhap news agency reported.

The person was moved to a larger hospital on Tuesday, but died after showing symptoms of blood poisoning and pneumonia, Yonhap said.

Another person in their 50s with a cardiac disorder and diabetes died on Wednesday after suffering multiple heart attacks, having received the same vaccine a day earlier, the agency said.

An official with the Korea Disease Control and Prevention Agency (KDCA) told Reuters it was investigating the cause of the deaths, but did not elaborate or confirm the details of Yonhap’s report.

An AstraZeneca spokesperson in Seoul said the company had no comment at present.

South Korea began vaccinating its population last week.

By Tuesday midnight, 85 904 people had received first doses of the AstraZeneca vaccine and 1 524 had been given Pfizer shots, KDCA said in a statement.

South Korea reported 444 new confirmed Covid-19 cases on Tuesday, up from 344 on Monday, raising the country’s tally to 90 816 infections, with 1 612 deaths.

Do you want to know more about this topic? Sign up for one of News24’s 33 newsletters to receive the information you want in your inbox. Special newsletters are available to subscribers.

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
%d bloggers like this: